research Wnt/β-catenin signalling: function, biological mechanisms, and therapeutic opportunities
The Wnt/β-catenin pathway is important for body functions and diseases, and targeting it may treat conditions like cancer, but with safety challenges.
Search
for
Sort by
Research
780-810 / 1000+ results research Biliary fibrosis is an important but neglected pathological feature in hepatobiliary disorders: from molecular mechanisms to clinical implications
Biliary fibrosis is crucial in liver diseases and understanding it can help prevent and treat these conditions.
research Perspective Chapter: Repurposing Natural Products to Target COVID-19 – Molecular Targets and New Avenues for Drug Discovery
Natural products might help treat COVID-19, but current drugs like hydroxychloroquine haven't worked.
research Research Advances in Therapeutic Strategies and Drug Delivery Systems for Pathological Scars
New drug delivery systems show promise in effectively treating pathological scars.
research Dysregulation of Leukaemia Inhibitory Factor (LIF) Signalling Pathway by Supraphysiological Dose of Testosterone in Female Sprague Dawley Rats During Development of Endometrial Receptivity
High testosterone levels can harm fertility by disrupting the LIF signaling pathway in the uterus.
research Epigenetic Mechanisms, Assessment and Therapeutics of Epidermal Stem Cells in Skin Aging
Epigenetic changes in skin cells contribute to aging, but targeting these changes may offer new antiaging treatments.
research Research Progress on the Immunomodulatory Effects by Dang Gui (Radix Angelica sinensis) and Its Active Chemical Components
Dang Gui may help treat immune-related diseases by boosting and regulating the immune system.
research Research Progress in Chronic Autoimmune Urticaria
Chronic autoimmune urticaria can be managed with specific therapies and requires improved diagnosis and treatment methods.
research Treatment of Alopecia Areata With Tofacitinib
Tofacitinib helped regrow hair in people with severe alopecia, but side effects occurred and benefits stopped after treatment ended.
research Ritlecitinib in severe alopecia areata: a profile of its use
Ritlecitinib effectively regrows hair in severe alopecia areata and is well tolerated.
research Drug pipeline 2Q22 — a downturn in approvals
Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.
research Tofacitinib for the treatment of alopecia areata and variants in adolescents
Tofacitinib helped regrow hair in most adolescents with alopecia areata, but more research is needed.
research How Long to Treat to Achieve Desired Treatment Outcomes with Baricitinib 4 mg in Severe Alopecia Areata: Evidence-based Approach
Baricitinib 4 mg should be used for at least 1 year to see significant hair regrowth in severe alopecia areata.
research Comparison of the Treatment Outcome of Oral Tofacitinib with Other Conventional Therapies in Refractory Alopecia Totalis and Universalis: A Retrospective Study
Tofacitinib works better and is more tolerable for severe alopecia than conventional treatments and DPCP immunotherapy.
research Efficacy and safety of tofacitinib in patients with alopecia areata
Tofacitinib helps hair regrowth in alopecia areata but relapse is common after stopping treatment.
research 1323 The effects of 3-OH of kaempferol on interfollicular epidermal stem cell fate
Kaempferol helps skin stem cells grow and may improve skin thickness due to its 3-OH group.
research 1324 Impairment of hair-inducing capacity of 3D-cultured human dermal papilla cells by the ablation of STAT5
Removing STAT5 from 3D-cultured human skin cells reduces their ability to grow hair.
research 1327 Effect of ginsenoside Rd on dermal epidermal junction in fibroblast
Ginsenoside Rd may help improve skin aging by increasing collagen in the skin.
research 1326 Hes1 regulates anagen initiation and hair follicle regeneration through modulation of hedgehog signaling
research Efficacy of Postbiotics in a PRP-Like Cosmetic Product for the Treatment of Alopecia Area Celsi: A Randomized Double-Blinded Parallel-Group Study
The PRP-like cosmetic product with postbiotics effectively treats hair loss in Alopecia areata.
research Real-World Evidence for Baricitinib in the Treatment of Atopic Dermatitis and Alopecia Areata: Systematic Literature Review 2020–2023
Baricitinib effectively improves symptoms of atopic dermatitis and alopecia areata with few side effects.
research New therapies for alopecia areata
New treatments for severe alopecia areata show promise but lack standard approval.
research Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata
Ritlecitinib is being tested for effectiveness and safety in treating severe alopecia areata.
research ORAL TOFACITINIB IN MODERATE AND SEVERE ALOPECIA AREATA: CASE SERIES OF 14 PATIENTS
Tofacitinib helped regrow hair in most patients with severe hair loss.
research Extensive alopecia areata is reversed by IL-12/IL-23p40 cytokine antagonism
Blocking IL-12/IL-23p40 helped reverse severe hair loss in patients.
research IL-12/IL-23 neutralization is ineffective for alopecia areata in mice and humans
Blocking IL-12/IL-23 does not help with hair loss in alopecia areata for mice or humans.
research Experience with oral tofacitinib in severe alopecia areata with different clinical responses
Oral tofacitinib helped regrow hair in over half of the patients with severe alopecia, but relapses and side effects were common.
research Alopecia Areata and Vitamin D3 Deficiency: The Potential of Calcipotriol as a Treatment
Calcipotriol's effectiveness for treating alopecia areata is unclear and needs more research.
research Impact of Previous Alopecia Areata Treatment on Efficacy Responses up to Week 48 Following Ritlecitinib Treatment: A Post Hoc Analysis
Previous alopecia areata treatments do not affect the long-term effectiveness of ritlecitinib.
research Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies
Ritlecitinib is effective and safe for long-term use in treating severe alopecia areata in people aged 12 and older.